Antibiotic Stewardship Targets Built for Hospitals Miss Nursing Homes
Hospital antibiotic stewardship programs count defined daily doses per 1,000 patient-days and publish antibiograms. Nursing homes, where a large share of residents receive antibiotics each year, report to payers rather than infection-control registries. The result is a policy gap that resistant organisms move through, from hospital bed to nursing home bed and back again.
Hospital Stewardship Metrics Dominate Policy
Antimicrobial stewardship refers to coordinated efforts to promote optimal use of antimicrobial agents, including drug choice, dose, route, and duration. In hospitals, this work has a measurement infrastructure. Pharmacy systems calculate defined daily doses per 1,000 patient-days, infection prevention teams track Clostridioides difficile rates, and microbiology labs produce annual antibiograms that show which organisms resist which drugs in that facility.
That infrastructure exists because accreditation and payment depend on it. In the United States, the Centers for Medicare & Medicaid Services requires hospitals to have antibiotic stewardship programs as a condition of participation. Similar requirements exist in parts of Europe and in the United Kingdom through national guidance.
The metrics are imperfect, but they create a feedback loop: prescribers see resistance patterns, pharmacists review orders, and leadership gets a dashboard. Nursing homes sit outside that loop. No comparable national reporting mandate covers long-term care in most high-income countries. A facility may track its own infections for internal quality purposes, but there is no standardized equivalent of the hospital antibiogram, no required denominator of resident-days, and no routine public reporting of antibiotic use. Policy targets built for hospitals simply do not reach the setting where many older adults receive their antibiotics.
Nursing Home Antibiotic Use Remains Unmeasured
Estimates suggest that up to 70 percent of nursing home residents receive at least one antibiotic course annually. That figure comes from studies that rely on pharmacy dispensing records, which capture prescriptions but not indications, or on chart reviews, which capture indications but depend on documentation quality. The two methods produce different denominators, and facilities vary in whether they count a course as a single order or as days of therapy. The direction is consistent across studies: a substantial share of those prescriptions are for asymptomatic bacteriuria, a condition that does not require treatment in most residents, or for long-term prophylaxis against urinary tract infections.
The prescribing pattern reflects the diagnostic environment. A urine sample is easy to obtain, and a positive culture is easy to act on. Distinguishing asymptomatic bacteriuria from a true urinary tract infection requires clinical judgment about symptoms, which is harder when a resident has dementia or communication difficulty. The default becomes treatment, often with broad-spectrum agents.
Facilities report to payers and regulators, not to infection-control registries. In the US, nursing homes submit the Minimum Data Set for assessment and quality reporting, but that instrument does not capture antibiotic days of therapy in a form comparable to hospital metrics.
Resistant Organisms Follow Discharge Pathways
MRSA and C. difficile travel with residents between settings. A patient treated in a hospital for a resistant infection is often discharged to a nursing home for post-acute care, carrying the organism into a new environment. Hospital stewardship gains can be offset by prescribing in the post-acute period, where the same patient may receive a different antibiotic for a different indication without the hospital pharmacist's review.
Regional prevalence varies widely. Some areas report MRSA colonization rates in nursing homes that exceed hospital rates, while others report lower figures. The variation depends partly on how intensively facilities culture and screen: a home that tests more will find more colonization, which may reflect testing practice rather than true differences in transmission. For policy, this means that surveillance data without a standardized testing denominator can mislead, and that comparing facilities requires knowing not just what they found but how hard they looked.
A related piece on this site has argued that screening programs stop at the clinic door, leaving patients to navigate the next step without support. The same structural problem appears here. A hospital identifies a resistant organism, treats it, and discharges the patient. The receiving facility may have no infection preventionist on staff and no system for flagging the organism on admission.
Payer Rules Shape Nursing Home Prescribing
Medicare Part A covers skilled nursing stays after a qualifying hospital admission, paying a per-diem rate that bundles most services. Part D covers outpatient drugs separately, with its own formulary and prior authorization rules. That split creates separate incentive structures. A facility may have little financial reason to invest in diagnostic confirmation when the test is not separately reimbursed, while the drug cost falls under a different payer.
Prior authorization for newer antibiotics shifts choices toward older, broader agents. When a prescriber knows that a request for a narrow-spectrum drug will take a day to approve, the path of least resistance is a drug already on formulary. That is a rational response to the incentive, not a knowledge gap.
Low reimbursement for diagnostic testing limits confirmation. A facility that wants to distinguish asymptomatic bacteriuria from infection may need to send a specimen to an outside lab, wait for results, and absorb the cost. This site has covered how payer rules price the same product two ways, and the same logic applies to diagnostics.
Equity Gaps in Access to Stewardship Support
Rural nursing homes lack on-site pharmacists. A facility with 60 beds may have no clinical pharmacist on staff and no contract with one. Urban facilities with academic affiliation fare better, often because they are part of a health system that already employs stewardship pharmacists for its hospitals and can extend that support to affiliated nursing homes.
Small homes cannot afford electronic surveillance tools. A system that flags duplicate antibiotic orders or calculates days of therapy requires an electronic health record with pharmacy data, which many independent facilities do not have. Consider a 90-bed home with one part-time clinical pharmacist and a basic EHR that logs medication orders as free-text nursing notes. Without discrete fields for drug, dose, and start date, the system cannot compute days of therapy, so the facility cannot track its own use over time or compare it to any benchmark. Workforce shortages constrain infection-prevention staffing. The certified infection preventionist role exists in hospitals, but in long-term care it is often a part-time responsibility assigned to a director of nursing who already has a full schedule.
These gaps are not evenly distributed. Facilities serving residents with lower incomes, or those in areas with fewer clinicians, are less likely to have the support that makes stewardship work. A policy that requires reporting without funding the infrastructure to report will widen the gap between facilities that can comply and those that cannot.
Practical Steps for Nursing Home Stewardship
Require antibiotic time-outs at 48 to 72 hours. A prescriber who starts an antibiotic for a suspected infection should document, at that interval, whether the indication still holds and whether a narrower agent would work. The time-out is a process measure that does not depend on a facility's budget for software.
Fund on-site or telephonic pharmacist review. A consulting pharmacist who reviews antibiotic orders weekly can catch duplicate therapy, unnecessary prophylaxis, and mismatches between culture results and drug choice. Telephonic models extend this support to rural facilities that cannot hire a full-time pharmacist.
Include nursing homes in regional resistance surveillance. A catchment-area antibiogram that combines hospital and long-term care data would show whether resistance patterns differ by setting and whether discharge pathways are seeding new facilities. This requires a reporting mandate and a funding stream to collect the data.
Tie payer bonuses to stewardship process measures. If a facility's payment depends on documenting time-outs and pharmacist review, those activities become routine. The trade-off is real: process measures can be gamed, and a facility that documents reviews without changing prescribing will still collect the bonus. Waiting for outcome measures that require years of data leaves the gap open longer, but it avoids rewarding paperwork that may not change prescribing.
Support diagnostic stewardship for urine cultures. Reflexive culturing of urine samples from residents without symptoms generates results that pressure clinicians to treat. A policy that limits culture ordering to residents with specific symptoms would reduce the number of positive results that do not represent infection.
This article is informational and does not constitute personalised medical or professional advice. Readers should consult qualified clinicians and local guidance for decisions about antibiotic use, infection control, and facility policy.
